Monte Rosa Therapeutics, Inc.
https://www.monterosatx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Monte Rosa Therapeutics, Inc.
Finance Watch: Cytokinetics Accesses Up To $1bn-Plus, Confirms No-Sale Plan
Public Company Edition: Cytokinetics executed a royalty financing deal for up to $575m and grossed $500m in a follow-on offering. Also, GSK grossed £1.25bn ($1.58bn) in sale of final Haleon shares, Bicycle raised $555m in a private placement and Apellis accessed up to $475m in debt.
Takeda Goes In On Molecular Glue Degraders With Degron Deal
The company will pay $1.2bn in upfront and milestone fees to access Degron’s GlueXplorer platform across multiple therapeutic areas.
BMS Spends $100m On Orum’s Antibody-Guided Protein Degrader
ORM-6151 combines two hot approaches in cancer R&D, but clinical trials have not yet started.
Roche Bonds With Monte Rosa To Degrade Molecular Glues
Deal Snapshot: Monte Rosa Therapeutics received $50m up front and may earn more than $2bn in milestone fees from Roche for molecular glue degraders to treat cancer and neurological diseases.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- ADMET
- Molecular Diversity
-
Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice